Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
- 1 April 2014
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 9 (4), 549-553
- https://doi.org/10.1097/jto.0000000000000094
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung CancerClinical Cancer Research, 2012
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in NeuroblastomaScience Translational Medicine, 2011
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practiceAnnals Of Oncology, 2011
- Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis ScreenChemical Biology & Drug Design, 2011
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProceedings of the National Academy of Sciences, 2011
- The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated CancersCancer Research, 2010
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature, 2008
- Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 2008
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000